Trajan Group Holdings Ltd · ASX:TRJ
Trajan — Shareholder Meeting (October 2025)
36 slides from Trajan's shareholder meeting presentation, Oct 28, 2025
Slide 1: 2025 Annual General Meeting Chair Address and Presentation
Global Corporate Headquarters 7 Argent Place, Ringwood Victoria 3134, Australia Tel: +61 (0) 3 9837 4200 www.trajanscimed.com Trajan Group Holdings Limited ACN 152 617 706 ASX RELEASE 2025 Annual General Meeting Chair Address and Presentation 28 October 2025 – Global analytical science and device co
Slide 2: Chair's Address
Chair’s Address Ladies and gentlemen, fellow shareholders, thank you for joining us at Trajan’s Annual General Meeting. It is both a privilege and a pleasure to stand before you today as Chair and reflect upon what makes our company truly special. Trajan Scientific and Medical draws its name from an
Slide 3: Chair's Address (conclusion)
At the conclusion of this address our CEO, Mr Stephen Tomisich will share a business update for this first quarter, and our plans for FY26. I’d like to thank Stephen and his team, and my fellow directors for their support throughout the year. I’d particularly like to thank Sara Watts for her dedicat
Slide 4: Annual General Meeting
For personal use only Science that benefits people Enriching personal health through scientific tools and solutions Annual General Meeting (ASX:TRJ) Trajan Scientific and Medical, Virtual Meeting, 28 October 2025, AEDT 10am
Slide 5: Your Board
YOUR BOARD For personal use only John Eales AM Stephen Tomisich Robert Lyon Tiffiny Lewin Sara Watts Dr Rohit Khanna Non-Executive Chair Founder, CEO and Executive Director Non-Executive Non-Executive Non-Executive Executive Director Director Director Director 2
Slide 6: Question Process
QUESTION PROCESS HOW TO ASK A QUESTION For personal use only • To ask a written question select the Q & A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below t
Slide 7: Voting Process
VOTING PROCESS HOW TO VOTE For personal use only • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is c
Slide 8: Address by the Chairman
Address by the Chairman Mr John Eales, AM For personal use only 5
Slide 9: CEO's Presentation
CEO’s Presentation Mr Stephen Tomisich For personal use only 6
Slide 10: AGM CEO Update
For personal use only Science that benefits people Enriching personal health through scientific tools and solutions AGM CEO Update Stephen Tomisich, CEO and Managing Director, Oct 28th, 2025.
Slide 11: FY2025 Financial Summary
FY2025 Financial Summary KEY POINTS REVENUE & EARNINGS FINANCIAL & CAPITAL DISCIPLINE For personal use only • Revenue: Increased contribution from all Segments despite $3.9M biotech Group Revenue $166.5M Cash $ 11.9M syringe loss. [PCP: $155.0M] Up 7.4% [PCP $11.2M] Up 5.4% • nEBITDA: Improved despi
Slide 12: FY26 Q1 Update: Revenue by Business Segment
FY26 Q1 Update Revenue by business Segment For personal use only Components and Consumables Capital Equipment Continued growth across the portfolio. Macro economic factors delaying orders in both USA and Q1 revenue up circa 10% on FY25. Europe, Asia outlook remains positive. Growth expected to conti
Slide 13: Q1 Milestones Achieved
Q1 Milestones Achieved Largest Customer For personal use only Agreement Extension through to mid 2030. Designed to collaborate around growth Sales Commenced and mutual cost savings. “HDExaminer Pro” First software release from Supply Chain Pivot MS Studio Platform acquired in 2024. Rapid “in region
Slide 14: Components and Consumables, the engine
Components and Consumables, the engine • Key Consumables Objectives FY26 • New Product Introductions and Extensions provide For personal use only examples of our diversification - all driving improved data • Build inventory position in Q2, integrity and accessibility avoid seasonal responsiveness ch
Slide 15: Capital Equipment, we know the pipeline
Capital Equipment, we know the pipeline • Key Capital Equipment Objectives FY26 For personal use only • Address margin expansion through pricing, pathways to market and streamlining internal processes • Continue to expand Service offering • Expand attachment rates • Trial “fee/sample” model in Clini
Slide 16: Disruptive Technologies
Disruptive Technologies For personal use only • Key Disruptive Objective FY26 • Versiti - address the remaining identified gaps to commercialisation • New Products and extensions; • Further progress Harpera microbiopsy towards commercialisation Harpera 13
Slide 17: Outlook
Outlook • Trajan is a resilient business • Long term fundamental growth drivers For personal use only • Diversity of markets, customers, geographies and operations • The acquired synergies will accelerate growth over time • Ongoing challenges, especially in capital equipment in FY26 • Margins • Marg
Slide 18: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 28th October 2025. The information in the presentation is provided for information purposes only, is in summary form and does no
Slide 19: For personal use only
For personal use only www.trajanscimed.com
Slide 20: Business of the Meeting
Business of the Meeting For personal use only 17
Slide 21: Financial Statements and Reports
Item 1 Financial Statements and Reports For personal use only The first item of business is to receive and consider the Company’s Annual Financial Report, including the Directors’ Report and Audit Report for the year ended 30 June 2025. Note: There is no vote required for this item. 18
Slide 22: Adoption of Remuneration Report
Resolution 1 Adoption of Remuneration Report For personal use only To consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of Section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report as contained in the D
Slide 23: Proxy Voting Results - Adoption of Remuneration Report
Proxy Voting Results - Resolution 1 Adoption of Remuneration Report For personal use only Number %² For 40,342,169 99.28 Against 290,494 0.71 Open – Chair¹ 4,618 0.01 Other 0 0.00 Abstain/Exclude 77,499,859 N/A ¹ To be voted in favour of the resolution ² Of proxies cast 20
Slide 24: Re-election of Dr Rohit Khanna as a Director
Resolution 2 Re-election of Dr Rohit Khanna as a Director For personal use only To consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That, Rohit Khanna, who retires in accordance with clause 12.5 of the Company’s Constitution and, being eligible, offers himse
Slide 25: Proxy Voting Results - Re-election of Dr Rohit Khanna
Proxy Voting Results – Resolution 2 Re-election of Dr Rohit Khanna as a Director For personal use only Number %² For 117,320,273 99.52 Against 569,720 0.48 Open – Chair¹ 4,618 0.00 Other 0 0.00 Abstain/Exclude 242,529 N/A ¹ To be voted in favour of the resolution ² Of proxies cast 22
Slide 26: Grant of Options to Director - Mr John Eales
Resolution 3 Grant of Options to Director – Mr John Eales For personal use only To consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 95,813 Op
Slide 27: Proxy Voting Results - Options to John Eales
Proxy Voting Results – Resolution 3 Grant of Options to Director – Mr John Eales For personal use only Number %² For 116,909,624 99.40 Against 704,915 0.60 Open – Chair¹ 4,987 0.00 Other 0 0.00 Abstain/Exclude 517,614 N/A ¹ To be voted in favour of the resolution ² Of proxies cast 24
Slide 28: Grant of Options to Director - Dr Rohit Khanna
Resolution 4 Grant of Options to Director – Dr Rohit Khanna For personal use only To consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 63,875
Slide 29: Proxy Voting Results - Options to Rohit Khanna
Proxy Voting Results – Resolution 4 Grant of Options to Director – Dr Rohit Khanna For personal use only Number %² For 117,174,739 99.40 Against 710,880 0.60 Open – Chair¹ 4,618 0.00 Other 0 0.00 Abstain/Exclude 246,903 N/A ¹ To be voted in favour of the resolution ² Of proxies cast 26
Slide 30: Grant of Options to Director - Ms Tiffiny Lewin
Resolution 5 Grant of Options to Director – Ms Tiffiny Lewin For personal use only To consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 63,875
Slide 31: Proxy Voting Results - Options to Tiffiny Lewin
Proxy Voting Results – Resolution 5 Grant of Options to Director – Ms Tiffiny Lewin For personal use only Number %² For 117,174,739 99.36 Against 750,415 0.64 Open – Chair¹ 4,618 0.00 Other 0 0.00 Abstain/Exclude 207,368 N/A ¹ To be voted in favour of the resolution ² Of proxies cast 28
Slide 32: Grant of Options to Director - Ms Sara Watts
Resolution 6 Grant of Options to Director – Ms Sara Watts For personal use only To consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 20,825 Op
Slide 33: Proxy Voting Results - Options to Sara Watts
Proxy Voting Results – Resolution 6 Grant of Options to Director – Ms Sara Watts For personal use only Number %² For 100,929,937 85.69 Against 16,853,960 14.31 Open – Chair¹ 4,618 0.00 Other 0 0.00 Abstain/Exclude 348,625 N/A ¹ To be voted in favour of the resolution ² Of proxies cast 30
Slide 34: Question & Answers
For personal use only Question & Answers 31
Slide 35: Voting and Meeting Close
Voting and Meeting Close Thank you. For personal use only If you have not yet voted, please proceed with voting now. The final results of the meeting will be advised to the ASX and will be available on Trajan’s investor website after the meeting. Thank you for your attendance. 32
Slide 36: For personal use only
For personal use only www.trajanscimed.com
Trajan Group Holdings — Shareholder Meeting (October 2025) on 6ix